Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indo-Bangla PharmaceuticalsDHA:IBP +6.67%32 Days Sales Outstanding is 505.09 as of Mar. 2026. GuruFocus rates DHA:IBP with a GF Score™ of 32/100. Among 947 Drug Manufacturers companies, Indo-Bangla Pharmaceuticals ranks worse than 105596.52% on this metric.
The historical rank and industry rank for Indo-Bangla Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:
DHA:IBP's Days Sales Outstanding is not ranked *
in the Drug Manufacturers industry.
Industry Median: 71.98 * Ranked among companies with meaningful Days Sales Outstanding only.
Indo-Bangla Pharmaceuticals's Days Sales Outstanding
declined
from Mar. 2025 (871.96) to Mar. 2026 (505.09).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals Days Sales Outstanding Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo-Bangla Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Indo-Bangla Pharmaceuticals's Days Sales Outstanding falls into.
Indo-Bangla Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 505.09 mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Days Sales Outstanding of 505.09 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Indo-Bangla Pharmaceuticals and its competitors. According to the industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 947 companies in the Drug Manufacturers industry.
Is Indo-Bangla Pharmaceuticals' Days Sales Outstanding too high?
Indo-Bangla Pharmaceuticals' current Days Sales Outstanding is 505.09. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Indo-Bangla Pharmaceuticals' value of 505.09 is 601.7% above this industry median. Based on the distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Days Sales Outstanding compare to ?
According to the Drug Manufacturers industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 947 companies for Days Sales Outstanding. This places Indo-Bangla Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Indo-Bangla Pharmaceuticals' value of 505.09 is 601.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo-Bangla Pharmaceuticals's current Days Sales Outstanding of 505.09 is 601.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Indo-Bangla Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo-Bangla Pharmaceuticals's current Days Sales Outstanding is 505.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Days Sales Outstanding of 505.09. The current Days Sales Outstanding is 505.09 and 601.7% above the Drug Manufacturers industry median of 71.98. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Days Sales Outstanding is 505.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score
Get the complete analysis for DHA:IBP
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBP has been successfully added to your 
